Articles with "vortioxetine" as a keyword



Vortioxetine‐induced syndrome of inappropriate secretion of antidiuretic hormone: A case report

Sign Up to like & get
recommendations!
Published in 2024 at "Neuropsychopharmacology Reports"

DOI: 10.1002/npr2.12438

Abstract: Vortioxetine, known for its efficacy in treating depression through its effects on various neurotransmitters, has not been previously reported to induce syndrome of inappropriate secretion of antidiuretic hormone (SIADH). read more here.

Keywords: secretion antidiuretic; syndrome inappropriate; vortioxetine; inappropriate secretion ... See more keywords
Photo from wikipedia

UPLC-MS/MS for simultaneous quantification of vortioxetine and its metabolite Lu AA34443 in rat plasma and its application to drug interactions

Sign Up to like & get
recommendations!
Published in 2020 at "Arabian Journal of Chemistry"

DOI: 10.1016/j.arabjc.2020.09.056

Abstract: Abstract Vortioxetine is currently used as the first-line therapy drug for major depressive disorder (MDD). In the present study, we aimed to develop and fully validate an ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS)… read more here.

Keywords: vortioxetine; drug; simultaneous quantification; metabolite aa34443 ... See more keywords

The rat hippocampal gliovascular system following one week vortioxetine and fluoxetine

Sign Up to like & get
recommendations!
Published in 2021 at "European Neuropsychopharmacology"

DOI: 10.1016/j.euroneuro.2020.11.008

Abstract: We have previously reported that vortioxetine, unlike the selective serotonin reuptake inhibitor fluoxetine, produces a rapid increase of dendritic spine number and Brain Derived Neurotrophic Factor (BDNF)-associated formation of synapses with mitochondrial support in the… read more here.

Keywords: rat hippocampal; vortioxetine; week vortioxetine; fluoxetine ... See more keywords

Vortioxetine 5, 10, and 20 mg Significantly Reduces the Risk of Relapse Compared With Placebo in Patients With Remitted Major Depressive Disorder: The RESET Study.

Sign Up to like & get
recommendations!
Published in 2022 at "Journal of affective disorders"

DOI: 10.1016/j.jad.2022.02.002

Abstract: BACKGROUND Maintenance therapy for major depressive disorder (MDD) is typically recommended at the dose on which the patient was stabilized. However, for some patients, dose alteration may be required. We investigated multiple vortioxetine doses versus… read more here.

Keywords: vortioxetine; placebo; depressive disorder; relapse ... See more keywords
Photo from wikipedia

Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients

Sign Up to like & get
recommendations!
Published in 2021 at "Progress in Neuro-Psychopharmacology and Biological Psychiatry"

DOI: 10.1016/j.pnpbp.2020.110016

Abstract: Escitalopram and vortioxetine are efficacious antidepressants. They directly target serotonin (5-HT) system, but vortioxetine mechanism of action is distinct from the one of selective serotonin reuptake inhibitors (SSRIs). Treatment with SSRIs decrease platelet 5-HT concentration… read more here.

Keywords: vortioxetine; plasma bdnf; platelet concentration; concentration ... See more keywords

Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD)

Sign Up to like & get
recommendations!
Published in 2018 at "CNS Spectrums"

DOI: 10.1017/s1092852918000913

Abstract: Objective The Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC) study aimed to assess the association between cognitive symptoms and work productivity in gainfully employed patients receiving vortioxetine for a major depressive… read more here.

Keywords: vortioxetine; productivity; major depressive; work productivity ... See more keywords

Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain

Sign Up to like & get
recommendations!
Published in 2019 at "Neuropsychopharmacology"

DOI: 10.1038/s41386-019-0442-4

Abstract: Vortioxetine is a multimodal antidepressant approved for treatment of major depressive disorder. Preclinical studies have demonstrated that the mechanism of action of vortioxetine might be different from selective serotonin reuptake inhibitors (SSRIs), including larger serotonin… read more here.

Keywords: vortioxetine; pet; relevant doses; effect ... See more keywords

Functional improvement as a treatment goal in major depressive disorder: a narrative review of the evidence for vortioxetine

Sign Up to like & get
recommendations!
Published in 2025 at "Current Medical Research and Opinion"

DOI: 10.1080/03007995.2025.2503976

Abstract: Abstract This narrative review used manufacturer-sponsored vortioxetine clinical trial database (doses of 5–20 mg) to evaluate the effect of vortioxetine treatment on short- and long- term functional outcomes in major depressive disorder (MDD), in both the… read more here.

Keywords: treatment; depressive disorder; major depressive; vortioxetine ... See more keywords

Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review.

Sign Up to like & get
recommendations!
Published in 2021 at "Expert opinion on drug safety"

DOI: 10.1080/14740338.2022.2019705

Abstract: INTRODUCTION Vortioxetine is a multimodal-acting antidepressant that provides improvements on cognitive function aside from antidepressants and anxiolytic effects. Vortioxetine has been found to be one of the most effective and best tolerated options for major… read more here.

Keywords: action; vortioxetine; depressive disorder; clinical studies ... See more keywords

Vortioxetine: a novel antidepressant for the treatment of major depressive disorder

Sign Up to like & get
recommendations!
Published in 2019 at "Expert Opinion on Drug Discovery"

DOI: 10.1080/17460441.2019.1546691

Abstract: ABSTRACT Introduction: Vortioxetine is a novel antidepressant drug approved for the treatment of major depressive disorder (MDD) in adults. It is formulated into tablets and has a dose range of 5–20 mg. The recommended starting… read more here.

Keywords: vortioxetine; depressive disorder; treatment major; major depressive ... See more keywords
Photo from wikipedia

Acneiform eruption associated with the use of vortioxetine

Sign Up to like & get
recommendations!
Published in 2019 at "Psychiatry and Clinical Psychopharmacology"

DOI: 10.1080/24750573.2018.1464633

Abstract: ABSTRACT Acneiform is used to describe eruptions that resemble acne vulgaris, but are not aetiologically similar. A number of drugs that can be responsible for acneiform eruptions exist. Vortioxetine is a multimodal antidepressant molecule that… read more here.

Keywords: vortioxetine; acneiform eruption; eruption associated; associated use ... See more keywords